key: cord-0825830-e7c9esie authors: Wu, Xiaosheng; Manske, Michelle K.; Ruan, Gordon; Nowakowski, Kevin E.; Abeykoon, Jithma P.; Tang, Xinyi; Yu, Yue; Witter, Taylor L.; Taupin, Vanessa; Paludo, Jonas; Ansell, Stephen M; Badley, Andrew D.; Schellenberg, Matthew J.; Witzig, Thomas E. title: Secreted ORF8 is a pathogenic cause of severe Covid-19 and potentially targetable with select NLRP3 inhibitors date: 2021-12-03 journal: bioRxiv DOI: 10.1101/2021.12.02.470978 sha: cfbbf38690c02ad7c47ee70824bf172d28fcfb9e doc_id: 825830 cord_uid: e7c9esie Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates the life-threatening inflammatory cytokine response in patients with severe Covid-19 remains unidentified. Herein we demonstrate that the virus-encoded Open Reading Frame 8 (ORF8) protein is abundantly secreted as a glycoprotein in vitro and in patients with newly diagnosed Covid-19. ORF8 specifically binds to the NOD-like receptor family pyrin domain-containing 3 (NLRP3) in CD14+/CD16+ monocytes to induce an inflammasomal cytokine response. The levels of ORF8 protein in the blood correlate with disease mortality in patients with acute infection, and the disease trajectory in patients with severe Covid-19. Furthermore, in vitro the ORF8-induced inflammasome response can be readily inhibited by the select NLRP3 inhibitor MCC950. Our results identify the pathogenic cause and mechanism of severe disease, and a potential new treatment of severe Covid-19. . m o n s t r a t e s t h a t t h e i n t e r m e d i a t e m o n o c y t e s u b s e t i s i n d e e d t h e p r i m a r y p r o d u c e r o f 148 p r o -i n f l a m m a t o r y c y t o k i n e s i n r e s p o n s e t o O R F 8 s t i m u l a t i o n . F 8 b u t n o t t h o s e o n l y p r e -i n c u b a t e d w i t h O R F 8 r e g a r d l e s s o f a c t i v a t i o n t i m e ( 3 o r 8 174 h o u r s ) . T h e s e r e s u l t s s t r o n g l y s u g g e s t O R F 8 l i k e l y e n t e r s m o n o c y t e s t h r o u g h a n o n -175 r e c e p t o r -m e d i a t e d p r o c e s s , s u c h a s p h a g o c y t o s 8 p r o t e i n l e v e l s c o r e l a t e w i t h t h e m o r t a l i t y a n d d i s e a s e c o u r s e o f s e v e r e p a t i e n t s w i t h 199 C o v i d -1 9 200 H a v i n g d e m o n s t r a t e d t h a t O R F 8 i s s e c r e t e d a s a g l y c o p r o t e i n a n d c a p a b l e D e s p i t e t h e e n o r m o u s s u c c e s s i n t h e d e v e l o p m e n t a n d i m p l e m e n t a t i o n o f 252 e f f e c t i v e v a c c i n e s t o p r e v e n t S A R S -C o V -2 i n f e c t i o n , C o v i d -1 9 r e m a i n s a m a j o r h e a l T h e N L R P 3 m e d i a t e d i n f l a m m a s o m e a c t i v a t i o n i s a c r u c i a l p a r t o f i n n a t e 277 i m m u n e r e s p o n s e t o p a t h o g e n -a s s o c i a t e d m o l e c u l a r p a t t e r n s ( P A M P s ) o r h o s t d a n g e r 278 a s s o c i a t e d p a t t e r n s ( D A M P s ) . W h e n n o t h r e a t s i g n a l i s p r e s e n t , N L R P 3 i s i n a n i n a c t i v t h e c e l l s w e r e c o l l e c t e d f o r c y t o k i n e m R N A d e t e c t i o n u s i n g q R T -P C R . T o t a l R N A s 342 i s o l a t e d u s i n g T r i z o l m e t h o d s , f o l l o w i n g c D N A s y n t h e s i s u s i n g s u p e r m i x I I I k i t s 343 ( T h e r m o F i s h e r ) , t h e e x p r e s s i o n o f v a r i o u s c y t o k i n e s w a s m e a s u r e d b y g e n e s w e r e e x c l u d e d f o r d o w n s t r e a m a n a l y s i s i n e a c h s a m p l e . F o r s c R N A -S e q a n a l y s i s , w e f o l l o w e d t h e S e u r a t i n t e g r a t i o n w o r k f l o w a n d t h e c o m p a r a t i v e a n a l y s i s w o r k f l o w . 368 E a c h d a t a s e t w a s n o r m a l i z e d a n d t h e t o p 2 0 0 0 H i g h l y V a r i a b l e G e n e s ( H V G s ) a c r o s s 369 c e l l s w e r e s e l e c t e d . T h e d a t a s e t s w e r e i n t e g r a t e d b a s e d o n " a n c h o r s " i d e n t i f i e d b e t w e e T r a n s f e c t e d H E K 2 9 3 F c e l l s w e r e g r o w n f o r 3 -4 d a y s a t a c e l l d e n s i t y b e l o w 6 x 1 0 6 393 c e l l s p e r m l . C e l l s w e r e p e l l e t e d b y c e n t r i f u g a t i o n a n d s u p e r n a t a n t c o n t a i n i n g s e c r e t e d 394 O R F 8 w a s s u p p l e m e n t e d w i t h C o m p l e t e -E D T A f r e e p r o t e a s e i n h i b i t o r c o c k t a i l ( R o c h e ) , D e t e c t i o n o f O R F 8 p r o t e i n i n s e r a o f p a t i e n t s n e w l y i n f e c t e d w i t h S A R S -C o V -2 419 F o r d e t e c t i o n O R F 8 p r o t e i n i n s e r u m s a m p l e s f r o m p a t i e n t s n e w l y i n f e c t e d w i t h 420 S A R S -C o V -2 , t y p i c a l l y f o u r m i c r o l i t e r s o f s e r u m d i r e c t l y m i x e d w i t h 3 7 m i c r o l i t e r s o f 4 Conditioned media containing secreted ORF8 specifically induced the Covid-19 specific cytokines (highlighted in yellow) IL1b, IL6, IL8, and CCL2 in PBMCs of some health donors . C. Pure highly glycosylated (yellow highlighted) but not unglycosylated ORF8 (unhighlighted) stimulates PBMCs to produce covid-19 specific (IL1b, IL6, IL8) cytokines but not IL2 . NSP2 NSP5 NSP7 NSP9 NSP10 NSP15 Nil NSP2 NSP5 NSP7 NSP9 NSP10 NSP15 NSP2 NSP5 NSP7 NSP9 NSP10 NSP15 NSP2 NSP5 NSP7 NSP9 NSP10 NSP15 B A Nil IL1b IL6 IL8 CCL2 IL10 TNFa CCL3 CCL5 GM-CSF IP10 ORF8-CM ORF8 induces IL1b production through non-surface receptor mediated process. PBMCs were pre-incubated on ice with ORF8 for 2 hours followed by washing and incubating at 37ºC to activate the cytokine production in the presence or absence of additional ORF8. C. ORF8 directly binds to NLRP3 but not TLR2/4 in primary monocytes; D. Systems biological assessment of immunity to mild versus 509 severe COVID-19 infection in humans COVID-19 and the human innate immune system Single cell RNA sequencing of 13 human tissues 513 identify cell types and receptors of human coronaviruses Single-cell RNA-seq data analysis on the receptor ACE2 expression 516 reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Detectable Serum Severe Acute Respiratory Syndrome Coronavirus Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 520 Level in Critically Ill Patients With Coronavirus Disease SARS-CoV-2 viral load is associated with increased disease severity 523 and mortality Longitudinal analyses reveal immunological misfiring in severe COVID-525 19 SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with 527 Covid-19 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients 529 with Covid-19 Structural 531 Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be A SARS-CoV-2 protein interaction map reveals targets for drug 534 repurposing Comparative host-coronavirus protein interaction networks reveal 536 pan-viral disease mechanisms Clinical features of patients infected with 2019 novel coronavirus in 538 Yanikkaya Demirel, G. & Sack, U. Monocytes and 540 macrophages in flow: an ESCCA initiative on advanced analyses of monocyte lineage 541 using flow cytometry Human Monocyte Subsets and Phenotypes in Major Chronic 543 Inflammatory Diseases COVID-19 vaccine efficacy in patients with chronic lymphocytic 545 leukemia Antibody response to SARS-CoV-2 vaccines in patients with 547 hematologic malignancies Genomic variance of the 2019-nCoV coronavirus Novel Immunoglobulin 551 Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-552 Related Viruses Integrated longitudinal immunophenotypic, transcriptional and 554 repertoire analyses delineate immune responses in COVID-19 patients A low level of CD16(pos) monocytes in SARS-CoV-2 infected patients 557 is a marker of severity From bacterial killing to immune modulation: Recent 559 insights into the functions of lysozyme The NLRP3 inflammasome: molecular activation 561 and regulation to therapeutics SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-565 deletion mutant and clade possibly associated with infections in Middle East Effects of a major deletion in the SARS-CoV-2 genome on the 568 severity of infection and the inflammatory response: an observational cohort study Early treatment of COVID-19 with anakinra guided by soluble 571 urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled 572 phase 3 trial Effect of anakinra on mortality in patients with COVID-19: a 574 systematic review and patient-level meta-analysis A new vector for high-throughput, ligation-independent cloning encoding 577 a tobacco etch virus protease cleavage site Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion 579 protein